
Report ID [TBO/RPT/YYYY/NNNN]
Version [v1 · final]
Issued [DD Month YYYY]
info@tribro-omics.com · +91 86603 08678 · tribro-omics.com
VARIANT TribroVariant Interpretation Report
Evidence-based classification of a single variant using ACMG/AMP criteria
1Patient and sample
| Patient name | [Surname, First name] |
|---|
| Patient ID / MRN | [ID] |
|---|
| Date of birth | [DD Month YYYY] |
|---|
| Sex | [Female / Male / Unknown] |
|---|
| Sample ID | [TBO-S-YYYY-NNNN] |
|---|
| Sample type | [EDTA blood / extracted DNA / saliva] |
|---|
| Collected | [DD Month YYYY] |
|---|
| Received | [DD Month YYYY] |
|---|
| Referring clinician | [Name, institution] |
|---|
| Clinical indication | [Phenotype summary; HPO terms, e.g. HP:0001250] |
|---|
2Test information
| Product | VARIANT Tribro — variant interpretation |
|---|
| Genome build | GRCh38 |
|---|
| Requested by | [Clinician / laboratory, reference] |
|---|
| Reason for request | [New interpretation / reclassification / second opinion] |
|---|
| Source of the variant | [Report or VCF supplied, date] |
|---|
3Variant
| Gene | [GENE] ([HGNC ID]) |
|---|
| Transcript | [NM_ ] (MANE Select) |
|---|
| cDNA / protein | [c. ] / [p. ] |
|---|
| Genomic (GRCh38) | [chrN:g. ] |
|---|
| Consequence | [Missense / nonsense / frameshift / splice / …] |
|---|
| Zygosity | [Het / Hom / Hemi] |
|---|
| Gene–disease association | [Disease (MIM), inheritance, ClinGen validity: Definitive / Strong / …] |
|---|
Classification
[Pathogenic / Likely pathogenic / Uncertain significance / Likely benign / Benign]
4Evidence (ACMG/AMP)
| Code | Strength | Applied | Evidence summary |
|---|
| PVS1 | [Very strong] | [Yes / No] | [Loss-of-function in a gene where LoF is a known mechanism] |
| PS / PM | [Strength] | [Yes / No] | [Functional, de novo, hotspot or absent-from-controls evidence] |
| PP / BP | [Supporting] | [Yes / No] | [Computational, segregation or phenotype evidence] |
| BA1 / BS | [Stand-alone / strong] | [Yes / No] | [Population frequency or other benign evidence] |
5Supporting data
| Source | Finding |
|---|
| gnomAD (v4) | [Allele count / frequency; homozygotes] |
| ClinVar | [Classification, review status, submitters] |
| In silico | [REVEL, CADD, SpliceAI scores] |
| Literature | [Key references, functional studies] |
| Segregation / de novo | [Family data] |
6Interpretation
[Explain how the combined evidence reaches the classification and what additional evidence could change it.]
7Limitations
- The classification is based on information available on the date of issue and the data supplied; the variant call itself was not re-verified unless stated.
- Variants of uncertain significance should not be used for clinical decision-making on their own.
8Recommendations
- Re-evaluate the classification when new evidence becomes available.
- Segregation or functional studies where they would change the classification.
9Sign-off
| Role | Name and qualification | Date |
|---|
| Analysed by (bioinformatics) | [Name, qualification] | [DD Month YYYY] |
| Reviewed by (clinical scientist) | [Name, qualification] | [DD Month YYYY] |
| Authorised by (laboratory director) | [Name, qualification] | [DD Month YYYY] |
10Important information
This report is intended for the referring clinician and must be interpreted together with the clinical findings, family history and other test results. Variant classification follows the ACMG/AMP 2015 standards (Richards et al., Genet Med 2015) and ClinGen Sequence Variant Interpretation recommendations. Classifications reflect the evidence available on the date of issue and may change. Genetic counselling is recommended when results are discussed with the patient. Report status: [Clinical / Research use only].